Search results for: Health Data and Statistics
Filter search results
Chris Skedgel
15 July 2019
…of scarce healthcare resources, including the use of cost-effectiveness and cost-utility frameworks to evaluate value-for-money and stated preference methods to elicit patient and public values. He has more than 60…
Amanda Cole
30 May 2014
Amanda Cole is a health economist specialising in economic evaluation, reimbursement, real-world evidence, and health policy. She leads OHE’s Economics of Innovation theme and is an Honorary Professor of Practice…
Andrew Briggs
9 December 2024
…Cost-Effectiveness Analysis (Wiley). With a career dedicated to advancing methodological research and practical applications, Andrew continues to influence academia and policy in health and beyond. Professor Biggs was awarded the…
2025 Wrapped: Health, policy shifts & what’s next
22 January 2026, 3:00pm
Share this: In January we recapped the biggest topics in health economics from 2025 across policy, prevention, and health technology assessments (HTA) and shared predictions and themes that will define…
Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
1 October 1997
…RPI-X price control (combining an increase for inflation with an efficiency target) and, where possible, the creation of market conditions which allow competition and so reduce or remove the need…
From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers
19 January 2016
…service or health system is the principal and the HTA agency the agent. An agency problem occurs if the preferences and incentives of the principal and agent do not align. …
From Efficacy to Cost-Effectiveness
1 May 1998
…of cost-effectiveness outcomes from efficacy data. There has been criticism of modelling, notably from the Food and Drug Administration (DDMAC, 1995) and the New England Journal of Medicine (Kassirer and Angel, 1994)….
Should Drug Prices Differ by Indication? The Debate on Indication-based Pricing
11 May 2018
…France, Germany, Italy, Spain and the UK. The “debate” around IBP centres on i) who benefits and who loses? and ii) how and whether it can be implemented in…
Uses of Models in Economic Evaluations of Medicines and Other Health Technologies
1 October 1996
…usually, the use of assumptions to enable extrapolation from the combined data or to fill gaps within the required data set. After categorising types of model and introducing us to…